Canaccord lowered the firm’s price target on Cara Therapeutics to $23 from $25 and keeps a Buy rating on the shares. The firm said we are encouraged that Korsuva IV is gaining momentum and they look forward to CARA’s internal readout on its Phase 3 study for oral Korsuva in atopic dermatitis that is coming later this year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CARA: